CY1118898T1 - Ανθρωπινα αντισωματα για πρωτεϊνη 4 τυπου ανθρωπινης αγγειοποιητινης - Google Patents

Ανθρωπινα αντισωματα για πρωτεϊνη 4 τυπου ανθρωπινης αγγειοποιητινης

Info

Publication number
CY1118898T1
CY1118898T1 CY20171100521T CY171100521T CY1118898T1 CY 1118898 T1 CY1118898 T1 CY 1118898T1 CY 20171100521 T CY20171100521 T CY 20171100521T CY 171100521 T CY171100521 T CY 171100521T CY 1118898 T1 CY1118898 T1 CY 1118898T1
Authority
CY
Cyprus
Prior art keywords
human
diseases
disorders
hangptl4
antibodies
Prior art date
Application number
CY20171100521T
Other languages
English (en)
Inventor
Mark W Sleeman
Viktoria Gusarova
Jee H Kim
Gang Chen
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of CY1118898T1 publication Critical patent/CY1118898T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Child & Adolescent Psychology (AREA)

Abstract

Παρέχεται ένα πλήρως ανθρώπινο αντίσωμα ή θραύσμα πρόσδεσης αντιγόνου ενός ανθρώπινου αντισώματος που προσδένεται ειδικά και αναστέλλει την πρωτεΐνη 4 τύπου ανθρώπινης αγγειοποιητίνης (hANGPTL4). Τα ανθρώπινα αντι-hANGPTL4 αντισώματα είναι χρήσιμα στη θεραπεία νόσων ή διαταραχών που σχετίζονται με την ANGPTL4, όπως υπερλιπιδαιμία, υπερλιποπρωτεϊναιμία και δυσλιπιδαιμία, περιλαμβάνοντας την υπερτριγλυκεριδαιμία, την υπερχοληστερολαιμία, την χυλομικροναιμία και ούτω καθεξής. Περαιτέρω, τα αντι-hANGPTL4 αντισώματα μπορούν να χορηγηθούν σε ένα υποκείμενο που χρήζει αυτών για την πρόληψη ή τη θεραπεία νόσων ή διαταραχών, για τις οποίες ο ανώμαλος μεταβολισμός των λιπιδίων αποτελεί παράγοντα κινδύνου. Τέτοιες νόσοι ή διαταραχές περιλαμβάνουν καρδιαγγειακές νόσους, όπως αθηροσκλήρωση και νόσους της στεφανιαίας αρτηρίας˙ οξεία παγκρεατίτιδα˙ μη αλκοολική στεατοηπατίτιδα (NASH)˙ διαβήτη˙ παχυσαρκία.
CY20171100521T 2009-12-24 2017-05-17 Ανθρωπινα αντισωματα για πρωτεϊνη 4 τυπου ανθρωπινης αγγειοποιητινης CY1118898T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US29009209P 2009-12-24 2009-12-24
US30635910P 2010-02-19 2010-02-19
US32831610P 2010-04-27 2010-04-27
US34927310P 2010-05-28 2010-05-28
US35612610P 2010-06-18 2010-06-18
PCT/US2010/061987 WO2011079257A2 (en) 2009-12-24 2010-12-23 Human antibodies to human angiopoietin-like protein 4

Publications (1)

Publication Number Publication Date
CY1118898T1 true CY1118898T1 (el) 2018-01-10

Family

ID=43629324

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100521T CY1118898T1 (el) 2009-12-24 2017-05-17 Ανθρωπινα αντισωματα για πρωτεϊνη 4 τυπου ανθρωπινης αγγειοποιητινης

Country Status (29)

Country Link
US (2) US8354103B2 (el)
EP (1) EP2516466B1 (el)
JP (2) JP6000855B2 (el)
KR (1) KR101842570B1 (el)
CN (1) CN102741284A (el)
AR (1) AR079708A1 (el)
AU (1) AU2010336369C1 (el)
BR (1) BR112012017765A2 (el)
CA (1) CA2785158C (el)
CY (1) CY1118898T1 (el)
DK (1) DK2516466T3 (el)
ES (1) ES2628135T3 (el)
HR (1) HRP20170524T1 (el)
HU (1) HUE034722T2 (el)
IL (1) IL220402A (el)
JO (1) JO3274B1 (el)
LT (1) LT2516466T (el)
MX (1) MX337082B (el)
NZ (1) NZ600768A (el)
PL (1) PL2516466T3 (el)
PT (1) PT2516466T (el)
RS (1) RS56009B1 (el)
RU (1) RU2580045C2 (el)
SG (1) SG181784A1 (el)
SI (1) SI2516466T1 (el)
TW (1) TWI488643B (el)
UY (1) UY33144A (el)
WO (1) WO2011079257A2 (el)
ZA (1) ZA201204507B (el)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
JP5813880B2 (ja) * 2011-09-19 2015-11-17 カイマブ・リミテッド ヒトへの使用に合わせて作製された抗体、可変ドメインおよび鎖
EP2836232A4 (en) * 2012-04-13 2016-03-16 Univ Johns Hopkins TREATMENT OF ISCHEMIC RETINOPATHIES
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
TW201823460A (zh) * 2012-05-29 2018-07-01 美商再生元醫藥公司 生產細胞株增強子
AU2013302925B2 (en) 2012-08-13 2018-07-05 Regeneron Pharmaceuticals, Inc. Anti-PCSK9 antibodies with pH-dependent binding characteristics
GB201301313D0 (en) * 2013-01-25 2013-03-06 Univ Singapore Respiratory Tract Infections
CA2912913A1 (en) * 2013-06-10 2014-12-18 Merck Sharp & Dohme Corp. Cmv neutralizing antigen binding proteins
KR101538787B1 (ko) * 2013-06-27 2015-07-22 인하대학교 산학협력단 췌장염 진단용 바이오 마커 조성물
CU24453B1 (es) 2014-08-07 2019-11-04 Novartis Ag Anticuerpos anti proteína similar a angiopoyetina 4
WO2016020882A2 (en) * 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
US9556225B2 (en) * 2014-10-15 2017-01-31 Uniao Quimica Farmaceutica Nacional S/A Peptide stimulator of cell survival and proliferation
WO2016181409A1 (en) 2015-05-11 2016-11-17 Cadila Healthcare Limited Saroglitazar magnesium for the treatment of chylomicronemia syndrome -
WO2017011929A1 (zh) * 2015-07-17 2017-01-26 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
CN107922507B (zh) 2015-08-18 2022-04-05 瑞泽恩制药公司 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
KR20190078650A (ko) 2016-11-17 2019-07-04 리제너론 파아마슈티컬스, 인크. 항-angptl8 항체를 사용하는 비만의 치료 방법
EP3565598A4 (en) 2017-01-03 2020-10-28 Trellis Bioscience, LLC NATIVE HUMAN ANTIBODIES FOR TIM-3 AND B7-H3 IMMUNE CHECKPOINT MODULATION TARGETS
US20190031774A1 (en) 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
CA3133633A1 (en) * 2019-03-20 2020-09-24 Javelin Oncology, Inc. Anti-adam12 antibodies and chimeric antigen receptors, and compositions and methods comprising
JP2023514000A (ja) * 2019-12-09 2023-04-05 エンピリコ インク． アンジオポエチン様４（ａｎｇｐｔｌ４）関連疾患の処置のためのオリゴヌクレオチド
TW202146442A (zh) 2020-02-26 2021-12-16 美商維爾生物科技股份有限公司 抗sars-cov-2抗體及使用其之方法
WO2022006555A2 (en) * 2020-07-02 2022-01-06 Gigagen, Inc. BISPECIFIC ANTIGEN BINDING PROTEINS TARGETING PD-L1 AND TGF-β AND METHODS OF USE
JP2023533253A (ja) * 2020-07-02 2023-08-02 マブリティクス， インコーポレイテッド 細胞結合タンパク質および使用の方法
WO2023239307A1 (en) * 2022-06-10 2023-12-14 Nanyang Technological University Methods of treating liver fibrosis, inflammation or associated diseases using an angptl4 antagonist
WO2024027708A1 (zh) * 2022-08-02 2024-02-08 诺纳生物（苏州）有限公司 Msln抗体药物偶联物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
RU2394839C2 (ru) * 2004-12-21 2010-07-20 Астразенека Аб Антитела против ангиопоэтина-2 и их применение
JP5366406B2 (ja) 2005-01-07 2013-12-11 レキシコン ファーマシューティカルズ インコーポレーテッド アンジオポエチン様タンパク質４（ａｎｇｐｔｌ４）に対するモノクローナル抗体
WO2007070671A2 (en) 2005-12-16 2007-06-21 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
AU2007227251A1 (en) * 2006-03-20 2007-09-27 Amgen Fremont, Inc. Antibodies directed to angiopoietin-like protein 4 and uses thereof
ES2398076T3 (es) 2006-06-02 2013-03-13 Regeneron Pharmaceuticals, Inc. Anticuerpos de alta afinidad contra el receptor de IL-6 humano
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).

Also Published As

Publication number Publication date
BR112012017765A2 (pt) 2017-06-20
US20130266574A1 (en) 2013-10-10
ZA201204507B (en) 2013-02-27
CA2785158A1 (en) 2011-06-30
TWI488643B (zh) 2015-06-21
ES2628135T3 (es) 2017-08-01
JP6000855B2 (ja) 2016-10-05
JP2013515486A (ja) 2013-05-09
MX2012007460A (es) 2012-08-23
KR20120104613A (ko) 2012-09-21
RS56009B1 (sr) 2017-09-29
JP2015145424A (ja) 2015-08-13
EP2516466B1 (en) 2017-03-15
US9120851B2 (en) 2015-09-01
AR079708A1 (es) 2012-02-15
NZ600768A (en) 2014-09-26
HRP20170524T1 (hr) 2017-06-02
CA2785158C (en) 2018-07-24
PT2516466T (pt) 2017-06-06
RU2012131547A (ru) 2014-01-27
AU2010336369A1 (en) 2012-07-12
WO2011079257A2 (en) 2011-06-30
PL2516466T3 (pl) 2017-09-29
US20110159015A1 (en) 2011-06-30
AU2010336369C1 (en) 2015-08-27
RU2580045C2 (ru) 2016-04-10
DK2516466T3 (en) 2017-05-15
TW201132354A (en) 2011-10-01
IL220402A (en) 2016-10-31
EP2516466A2 (en) 2012-10-31
UY33144A (es) 2011-06-30
SG181784A1 (en) 2012-07-30
LT2516466T (lt) 2017-05-25
CN102741284A (zh) 2012-10-17
JO3274B1 (ar) 2018-09-16
KR101842570B1 (ko) 2018-03-28
US8354103B2 (en) 2013-01-15
SI2516466T1 (sl) 2017-06-30
HUE034722T2 (en) 2018-02-28
AU2010336369B2 (en) 2015-06-04
MX337082B (es) 2016-02-11
WO2011079257A3 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
CY1118898T1 (el) Ανθρωπινα αντισωματα για πρωτεϊνη 4 τυπου ανθρωπινης αγγειοποιητινης
CY1120996T1 (el) Αντισωματα anti-angptl3 και χρησεις αυτων
CY1124902T1 (el) Μεθοδοι αντιμετωπισης της υπερλιπιδημιας με αναστολεα angptl8 και αναστολεα angptl3
CY1124412T1 (el) Aνti-dkk-1 αντισωματα
CY1124166T1 (el) Συζευγματα αντισωματος φαρμακου (adc) τα οποια δεσμευονται σε 191p4d12 πρωτεϊνες
CY1119751T1 (el) Υλικα και μεθοδοι για θεραπεια ή προληψη ασθενειων που σχετιζονται me her-3
CY1121431T1 (el) Μορια αντισωματος που εχουν ειδικοτητα για τον ανθρωπινο οχ40
NZ593314A (en) Dual variable domain immunoglobulins and uses thereof
UA107600C2 (uk) АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ
NZ703481A (en) Cd37-binding molecules and immunoconjugates thereof
BR112013004581A2 (pt) imunoglobulinas de domínio variável dual e seus usos
BRPI0819916A2 (pt) Proteína de ligação a antígeno, composição farmacêutica, método para tratar um paciente humano afligido com uma doença, anticorpo ou fragmento do mesmo, e, proteína de ligação a antígeno.
MX2012005037A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2012002651A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX2012001262A (es) Inmunoglobulinas de dominio variable doble y usos de las misma.
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
EA201500064A1 (ru) Активаторы ampk и их применение в терапевтических целях
BRPI0911520A2 (pt) novas aproximações terapêuticas para o tratamento da doença de alzheimer e doenças relacionadas através de uma modulação de angiogênese.
EA201100923A1 (ru) Антитела человека против тканевого фактора
EP2016173A4 (en) METHOD AND COMPOSITIONS FOR TREATING HUMAN IMMUNODEFECT VIRUS INFECTIONS WITH CONJUGATED ANTIBODIES OR ANTIBODY FRAGMENTS
CY1116823T1 (el) Στοχευση abcb5 για θεραπεια καρκινου
UY31466A1 (es) Anticuerpos monoclonales que se unen al hgm-csf y las composiciones médicas que los comprenden
EA201201120A1 (ru) Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 161p2f10b
UA101681C2 (ru) Изолированное антитело, которое специфически связывается с рецептором фактора роста фибробластов -3 и фармацевтическая композиция, которая содержит указанное антитело
EA201300130A1 (ru) Способ лечения болезни альцгеймера